YD Bio (YDES)
Builds cancer-testing and ophthalmology programs alongside clinical-trial drug supply.
$3.74
Pre-market−0.16 (−4.10%)
At close$3.90(+3.31%)
In millions of USD, except per-share figures
| In millions | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 |
|---|---|---|---|---|---|---|---|
| 1 | 1 | 1 | 0 | 0 | 0 | 0 | |
| Selling, general & administrative | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Operating income | −1 | −1 | −1 | 0 | 0 | 0 | 0 |
| 1 | −21 | 18 | 2 | 1 | −3 | −2 | |
| Interest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income | −1 | 21 | −18 | −2 | −1 | 3 | 2 |
| Income before tax | 1 | −22 | 17 | 2 | 0 | −3 | −2 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | 1 | −22 | 17 | 2 | 0 | −3 | −2 |
| Net income | 1 | −22 | 17 | 2 | 0 | −3 | −2 |
| EPS, basic | $0.16 | −$5.12 | $4.05 | $0.54 | $0.10 | −$0.98 | −$0.65 |
| EPS, diluted | $0.16 | −$5.12 | $4.05 | $0.54 | $0.10 | −$0.98 | −$0.65 |
| Weighted average shares, basic | 4 | 4 | 4 | 4 | 4 | 3 | 3 |
| Weighted average shares, diluted | 4 | 4 | 4 | 4 | 4 | 3 | 3 |
| EBITDA | 1 | −22 | 17 | 2 | 0 | −3 | −2 |
| EBIT | 1 | −22 | 17 | 2 | 0 | −3 | −2 |